

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

**VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING BY DIRECTORS AND SENIOR
MANAGEMENT
AND
EXERCISE OF OPTIONS BY A DIRECTOR**

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

INCREASE IN SHAREHOLDING BY DIRECTORS AND SENIOR MANAGEMENT

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has been informed by the executive Director and certain members of the Company’s senior management that, from July 14 to July 16, 2025, they had purchased a total of 900,000 shares of the Company (the “**Shares**”) on the open market with an average trading price of HK\$7.257 (the “**Shareholding Increase**”).

EXERCISE OF OPTIONS BY A DIRECTOR

The Board was further informed by Dr. Xu Ting, the chief executive officer and an executive Director of the Company that following the exercise of 4,552,950 options on May 21, 2020, closing price of the Shares immediately before that day being HK\$23.10, under the pre-IPO share option plan I adopted by the Company on October 16, 2018, as amended from time to time (the “**Pre-IPO Share Option Plan I**”), he has further exercised 9,005,890 options vested to him under the Pre-IPO Share Option Plan I on July 16, 2025, closing price of the Shares immediately before that day being HK\$7.49 (the “**Exercise of Options**”).

The aforementioned Directors and senior management members have expressed strong confidence in the Company’s overall development prospects, growth potential, and the long-term investment value of its Shares. Subject to compliance with applicable laws and regulatory requirements, they will not rule out the possibility of further increasing their shareholdings in the Company as and when appropriate.

Based on the information available to the Company and to the knowledge of the Board, following the completions of the Exercise of Options and the Shareholding Increase, the Company maintains a sufficient public float of its issued Shares in compliance with the applicable laws, rules and provisions, including the Rule 8.08 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); and the Exercise of Options and the Shareholding Increase have been conducted in compliance with the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, July 16, 2025

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Ms. WONG Yan Ki Angel, Dr. GAO Xiang and Mr. WU Dong as independent non-executive Directors.